ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.50M | $9.16M | $15.62M | $30.98M | $9.19M | $13.75M | $990.00K |
| Cost of Revenue | N/A | $1.02M | $64.32M | $47.11M | $44.85M | $24.94M | $38.99M |
| Gross Profit | $3.50M | $8.14M | $-48.70M | $-16.12M | $-35.65M | $-11.19M | $-38.00M |
| Gross Margin | 100.00% | 88.86% | -311.84% | -52.03% | -387.79% | -81.33% | -3837.98% |
| Operating Expenses | $40.50M | $83.56M | $22.20M | $18.02M | $8.87M | $7.31M | $2.90M |
| Operating Income | $-37.00M | $-75.42M | $-70.90M | $-34.14M | $-44.52M | $-18.49M | $-40.89M |
| Operating Margin | -1057.14% | -823.33% | -453.99% | -110.18% | -484.22% | -134.46% | -4130.71% |
| Net Income | $-36.57M | $-68.17M | $-68.77M | $-34.12M | $-44.26M | $-16.82M | $-40.87M |
| Net Margin | -1044.80% | -744.17% | -440.29% | -110.10% | -481.36% | -122.28% | -4127.78% |
| EPS (Basic) | $-1.02 | $-1.63 | $-1.90 | $-0.95 | $-3.16 | $-0.47 | $-1.14 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |